Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3611 - ESR1, Ph-mTOR, CDK4/6 and PD-L1 expression as prognostic (and potentially druggable) drivers for pure Invasive Lobular breast Carcinoma (ILC): preliminary results of prognostic outliers according to a clinical-pathological model.


11 Sep 2017


Poster display session


Breast Cancer


Luisa Carbognin


Annals of Oncology (2017) 28 (suppl_5): v43-v67. 10.1093/annonc/mdx362


L. Carbognin1, M. Brunelli2, E. Manfrin2, A. Caliò2, I. Sperduti3, M.V. Dieci4, G. Griguolo4, V. Guarneri4, R. Nortilli1, S. Pilotto1, E. Fiorio5, V. Parolin5, E. Orvieto6, F. Pellini7, G.P. Pollini7, P.F. Conte8, A. Scarpa2, G. Tortora1, E. Bria1

Author affiliations

  • 1 Medical Oncology, University of Verona, 37134 - Verona/IT
  • 2 Department Of Pathology And Diagnostics,, University and Hospital Trust of Verona, Verona/IT
  • 3 Biostatistics, Regina Elena National Cancer Institute, Rome/IT
  • 4 Department Of Surgery, Oncology And Gastroenterology, University of Padova, 35128 - Padova/IT
  • 5 Oncology, AOU Integrata Verona, 37126 - Verona/IT
  • 6 Department Of Surgery, Oncology And Gastroenterology, Istituto Oncologico Veneto, 35128 - Padova/IT
  • 7 Breast Surgery, AOU Integrata Verona, 37126 - Verona/IT
  • 8 Medical And Experimental Oncology Department, Medical Oncology 2, Istituto Oncologico Veneto IRCCS, 35128 - Padova/IT


Abstract 3611


The biological drivers of prognosis for pure ILC are not entirely clear. The aim of this analysis was to investigate the molecular and immune-related portrait of prognostic outliers to identify different patterns of expression associated with prognosis and potentially druggable.


Clinical-pathological multi-center data of resected early-stage pure ILC patients (pts) were correlated to disease-free and overall-survival (DFS/OS). A continuous score was derived according to multivariate Hazard Ratios, in order to derive a 3-class model (Poor/Intermediate/Good Prognosis). IHC (for Ph-mTOR, CDK6, PD-L1), FISH (for ESR1, Ph-mTOR, CDK4, PD-L1) and H&E evaluation (for stromal Tumor Infiltrating Lymphocytes, sTILs) were performed upon pts at Poor and Good Prognosis. Odds Ratio (OR) with 95% CIs for the risk of association with prognostic class of biomarkers was determined.


Data from 457 pts were gathered (median age 57 years, median follow: 75 months). The 3-class cross-validated model significantly differentiated DFS and OS (p 


Despite unpowered, these preliminary data suggest that Poor and Good prognosis are potentially associated to differential expression of a cluster of biomarkers: ESR1 deletion, CDK4 gain, CDK6 and ph-mTOR over-expression versus high sTILs, PD-L1 positive, ESR1 gain and ph-mTOR deletion, respectively.

Clinical trial identification

Not applicable.

Legal entity responsible for the study

University of Verona




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.